```
### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES
PLEASE LOGON:
 ******** HHHHHHHH SSSSSSSS?
### Status: Signing onto Dialog
 ********
ENTER PASSWORD:
 ******** HHHHHHHH SSSSSSSS? ********
Welcome to DIALOG
### Status: Connected


Dialog level 04.05.14D

Last logoff:  21apr04 13:43:33
Logon file001 22apr04 08:37:14
           *** ANNOUNCEMENT ***
                    ***
--File 654 - US published applications from March 15, 2001 to the
present are now online.  Please see HELP NEWS 654 for details.

                    ***
--File 581 - The 2003 annual reload of Population Demographics is
complete. Please see Help News581 for details.

                   ***
--File 990 - NewsRoom now contains February 2003 to current records.
File 992 - NewsRoom 2003 archive has been newly created and contains
records from January 2003. The oldest months's records roll out of
File 990 and into File 992 on the first weekend of each month.
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new
OneSearch category.
                    ***
--Connect Time joins DialUnits as pricing options on Dialog.
See HELP CONNECT for information.
                    ***
                    ***
--SourceOne patents are now delivered to your email inbox
as PDF replacing TIFF delivery. See HELP SOURCE1 for more
information.
                    ***
--Important Notice to Freelance Authors--
See HELP FREELANCE for more information
                    ***
NEW FILES RELEASED
***AeroBase (File 104)
***DIOGENES: Adverse Drug Events Database (File 181)
***World News Connection (File 985)
***Dialog NewsRoom - 2003 Archive (File 992)
***TRADEMARKSCAN-Czech Republic (File 680)
***TRADEMARKSCAN-Hungary (File 681)
***TRADEMARKSCAN-Poland  (File 682)
                    ***
UPDATING RESUMED
                    ***
RELOADED
***Medline (Files 154-155)
***Population Demographics -(File 581)
***CLAIMS Citation (Files 220-222)

REMOVED
                    ***
```

```
      >>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
      >>>    of new databases, price changes, etc.      <<<
                    ****
KWIC is set to 50.
HILIGHT set on as '*'
*
*
* ALL NEW CURRENT YEAR RANGES HAVE BEEN * * *
* * * INSTALLED   * * *
*

File   1:ERIC 1966-2004/Mar 31
       (c) format only 2004 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?b 155, 159, 5, 73
       22apr04 08:37:26 User259876 Session D612.1
            $0.31    0.088 DialUnits File1
     $0.31  Estimated cost File1
     $0.05  TELNET
     $0.36  Estimated cost this search
     $0.36  Estimated total session cost   0.088 DialUnits


SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1966-2004/Apr W3
         (c) format only 2004 The Dialog Corp.
*File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.
  File 159:Cancerlit 1975-2002/Oct
         (c) format only 2002 Dialog Corporation
*File 159: Cancerlit ceases updating with immediate effect.
Please see HELP NEWS.
  File   5:Biosis Previews(R) 1969-2004/Apr W2
         (c) 2004 BIOSIS
  File  73:EMBASE 1974-2004/Apr W2
         (c) 2004 Elsevier Science B.V.

      Set  Items  Description
      ---  -----  -----------
?s (PSA) (s) (T (w) cell (w) epitope)
Processing
          34205  PSA
        5250380  T
        8228883  CELL
         102100  EPITOPE
      S1       0  (PSA) (S) (T (W) CELL (W) EPITOPE)
?s (PSA) (s) (epitope)
          34205  PSA
         102100  EPITOPE
      S2     266  (PSA) (S) (EPITOPE)
?s s2 (s) (vector or plasmid)
            266  S2
         281589  VECTOR
         195683  PLASMID
      S3       6  S2 (S) (VECTOR OR PLASMID)
?rd
...completed examining records
      S4       2  RD (unique items)
?t s4/3,k/all

 4/3,K/1     (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
```

15864342 PMID: 14770085

CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.

Klyushnenkova Elena N; Ponniah Sathibalan; Rodriguez Alejandro; Kodak James; Mann Dean L; Langerman Alexander; Nishimura Michael I; Alexander Richard B

Division of Urology, VA Maryland Health Care System, Baltimore, Maryland, USA. eklyushnenkova@smail.umaryland.edu

Journal of immunotherapy (Hagerstown, Md. - 1997) (United States) Mar-Apr 2004, 27 (2) p136-46, ISSN 1524-9557 Journal Code: 9706083

Contract/Grant No.: CA82888; CA; NCI; CA90873; CA; NCI; DK-53732; DK; NIDDK

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

In order to develop immunotherapies for prostate cancer, many groups are exploring vaccination strategies to induce an immune response against prostate specific antigen (*PSA*). To determine if T-cell recognition of *PSA* might be a feature of a naturally occurring human disease, we have studied patients with prostatitis, a poorly understood clinical syndrome of men in which there is evidence that an immune response directed against the prostate may be occurring. We wished to determine if a T-cell response to *PSA* might be occurring in these patients. We generated long-term T-cell lines from peripheral blood mononuclear cells (PBMC) of one patient with granulomatous prostatitis using purified *PSA* as an antigen. Several CD4+ and CD8+ TcR alpha/beta+ T-cell lines were selected for *PSA* reactivity as measured by at least a threefold increase in IFN-gamma secretion in response to *PSA* presented by irradiated autologous PBMC. CD4 and CD8 T-cell lines recognized *PSA* in the context of HLA-DRbeta1*1501 and HLA-B*0702, respectively. The specificity and HLA restriction of the lines was confirmed using EBV-B cell lines infected with a recombinant *PSA* -expressing vaccinia virus and also engineered to express *PSA* by retroviral transfection. HLA-matched targets infected by control *vector* as well as HLA-mismatched *PSA* -expressing targets did not induce the response. The data demonstrate that *PSA*-specific T cells are present in the PBMC of this patient with granulomatous prostatitis, who may be manifesting naturally the type of immune response directed at the prostate that is the goal of prostate cancer immunotherapy. However, the Class I-restricted *epitope* has not yet been demonstrated to be expressed on the surface of prostate cancer cells. To our knowledge, this is the first demonstration of HLA-DRB1*1501- or HLA-B*0702-restricted responses to *PSA* and extends the number of HLA molecules accommodating the use of *PSA* antigen as a candidate vaccine for prostate cancer immunotherapy.

4/3,K/2 (Item 2 from file: 155)

11626283 PMID: 11801539

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa Hiroshi; Tsang Kwong-Yok; Gulley James; Arlen Philip; Schlom Jeffrey

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Clinical cancer research - an official journal of the American Association for Cancer Research (United States) Jan 2002, 8 (1) p41-53, ISSN 1078-0432 Journal Code: 9502500

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

One potential target of vaccine therapy for human prostate cancer is the prostate-specific antigen (*PSA*). One strategy to enhance the immunogenicity of a self-antigen such as *PSA* is to develop agonist epitopes that are potentially more immunogenic. The studies described here report the design and analysis of an agonist *epitope* designated *PSA*-3A ("A" for agonist) of the *PSA*-3 CTL *epitope*. Studies demonstrate that when compared with the native *PSA*-3 *epitope*, the *PSA*-3A agonist demonstrates enhanced binding to the MHC class I A2 allele as well as enhanced stability of the peptide-MHC complex. T-cell lines generated with either the *PSA*-3 or the *PSA*-3A peptide showed higher levels of lysis of targets pulsed with the *PSA*-3A peptide than those targets pulsed with the *PSA* -3 peptide; this was observed when both the concentration of peptide and the ratio of effector to target cells were titrated. T cells stimulated with dendritic cells (DCs) pulsed with *PSA*-3A peptide produced higher levels of IFN-gamma than did DCs pulsed with *PSA*-3 peptide; however, no increase in apoptosis was seen in T cells stimulated with the *PSA*-3A agonist compared with those stimulated with *PSA*-3. Human T-cell lines generated with the *PSA*-3A agonist had the ability to lyse human prostate carcinoma cells expressing native *PSA* in an MHC-restricted manner. Recombinant vaccinia viruses were also constructed that contained the entire *PSA* transgene with and without the single amino acid change that constitutes the *PSA*-3A *epitope*; DCs infected with the recombinant *vector* containing the agonist amino acid change within the entire *PSA* gene (designated rV-*PSA*-3A) were more effective than DCs infected with the rV-*PSA* *vector* in enhancing IFN-gamma production by T cells. Finally, the *PSA*-3A agonist was shown to induce higher levels of T-cell activation, compared with the *PSA*-3 peptide, in an in vivo model using HLA-A2.1/K(b) transgenic mice. These studies thus demonstrate the potential use of the *PSA*-3A agonist *epitope* in both peptide- and *vector* -mediated immunotherapy protocols for prostate cancer.

```
?ds

Set     Items   Description
S1          0   (PSA) (S) (T (W) CELL (W) EPITOPE)
S2        266   (PSA) (S) (EPITOPE)
S3          6   S2 (S) (VECTOR OR PLASMID)
S4          2   RD (unique items)
?s (KLQCVDLHV) (s) (PSA)
                0  KLQCVDLHV
            34205  PSA
      S5        0  (KLQCVDLHV) (S) (PSA)
?s s2 and (vector or plasmid)
              266  S2
           281589  VECTOR
           195683  PLASMID
      S6        7  S2 AND (VECTOR OR PLASMID)
?s s6 not s3
                7  S6
                6  S3
      S7        1  S6 NOT S3
?t s7/3,k/all

 7/3,K/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2004 BIOSIS. All rts. reserv.

0010917562   BIOSIS NO.: 199799551622
```

Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen

AUTHOR: Eerola Riitta; Piironen Timo; Pettersson Kim; Lovgren Janita; Vehnianen Markus; Lilja Hans; Dowell Barry; Lovgren Timo; Karp Matti (Reprint)
AUTHOR ADDRESS: Dep. Biotechnol., Univ. Turku, FIN-20520 Turku, Finland** Finland
JOURNAL: Prostate 31 (2): p84-90 1997 1997
ISSN: 0270-4137
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: glandular kallikrein (KLK2) was expressed in Escherichia coli, and the corresponding protein (hK2) was produced by fermentation. The hK2 was characterized by Western blotting and *epitope* map using monoclonal antibodies (MAbs) specific for another protease, prostate-specific antigen (*PSA*) with high structural identity (80%). MAbs that recognized three different epitopes were bound to hK2, representing 7 out of 23 MAbs tested. One *epitope* was localized to the sequence region around amino acid position 78, which is believed to be glycosylated in hK2. The affinities of MAbs recognizing hK2 were similar to those for *PSA*, suggesting that common epitopes seem to contain very conserved structures. The results may help in designing specific diagnostic assays for the assessment of prostate cancer.
DESCRIPTORS:
MISCELLANEOUS TERMS: ...GENE EXPRESSION *VECTOR*;
?ds

Set	Items	Description
S1	0	(PSA) (S) (T (W) CELL (W) EPITOPE)
S2	266	(PSA) (S) (EPITOPE)
S3	6	S2 (S) (VECTOR OR PLASMID)
S4	2	RD (unique items)
S5	0	(KLQCVDLHV) (S) (PSA)
S6	7	S2 AND (VECTOR OR PLASMID)
S7	1	S6 NOT S3

?logoff
22apr04 08:42:21 User259876 Session D612.2
$1.67 0.523 DialUnits File155
$0.42 2 Type(s) in Format 3
$0.42 2 Types
$2.09 Estimated cost File155
$0.56 0.189 DialUnits File159
$0.56 Estimated cost File159
$3.60 0.643 DialUnits File5
$1.75 1 Type(s) in Format 3
$1.75 1 Types
$5.35 Estimated cost File5
$9.42 0.961 DialUnits File73
$9.42 Estimated cost File73
OneSearch, 4 files, 2.315 DialUnits FileOS
$1.25 TELNET
$18.67 Estimated cost this search
$19.03 Estimated total session cost 2.403 DialUnits

Status: Signed Off. (6 minutes)